SUWANEE, GA, March 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB:
SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive,
biological response activating devices in regenerative medicine, is excited to announce winning the JWC’s (Journal of Wound Care)
2019 Innovation in Chronic Wound Healing Award for dermaPACE® pressure shockwave for wound management.
The JWC is the definitive wound-care journal and the leading source of up-to-date research and clinical information on
everything related to tissue viability. The journal was first launched in 1992 and caters to the needs of the multidisciplinary
team. JWC is the official journal of the World Union of Wound Healing Societies (WUWHS); it is also the media partner of the
European Wound Management Association (EWMA) and affiliated to over 40 other associations, societies and charities. In the United
States JWC is affiliated with AAWC, NPUAP and APWH giving unrivaled access to the global wound care community.
The JWC Awards annually seek to recognize the significant work done by health care professionals in all fields of
wound care, benchmarking standards within wound care to highlight the contributions and commitment that nurses, clinicians,
scientists, researchers, and academics make to the development of wound-care research and practice. JWC winners are chosen by a
prominent panel of expert judges that are representative of the diversity of disciplines and organizations that make up the
sector.
President of SANUWAVE, Shri Parikh, who was in attendance to receive the award in London on the evening of March
1, said, “SANUWAVE had significant competition in the category. It was a humbling honor to hear that SANUWAVE was chosen as the
award winner to represent chronic wound healing innovation.”
CEO and Chairman of the Board at SANUWAVE, Kevin Richardson, equally humbled, also weighed in stating that, “Any
wound that does not follow a normal healing trajectory can be described as chronic. These patients often have a number of
perplexing factors including a long and challenging treatment road ahead of them, that at times leads to amputation if the wound is
not able to heal properly. Nothing gives us a greater feeling of reward and accomplishment than to see SANUWAVE contributing to the
healing process, patient quality of life and science innovation. Pete Stegagno, Chief Operating Officer and Iulian Cioanta, Chief
Science and Technology Officer made tremendous contributions to this innovation effort and we are thrilled to have these talented
individuals on the SANUWAVE Executive Team.”
If you would like to reference all 2019 JWC winners, please click here: https://www.jwcawards.com/winners
About the JWC (Journal of Wound Care Management)
The JWC is England’s leading tissue viability and wound care professionals journal for nurses, medics, and
researchers working in wound care. The JWC is essential reading for wound care professionals who are serious about providing the
best possible support for the people in their care, and those who want to keep on top of the latest thinking and research.
Registrants receive a free issue of Journal of Wound Care, unlimited access to the CPD launchpad, instant access to the 10 free
supplement downloads, a free copy of the 'Wound Care Handbook' 2017/2018, cutting edge research articles from leading specialists,
advice on managing tissue viability services, and coverage of the latest developments in tissue viability education.
For additional information about the JWC, visit: https://info.journalofwoundcare.com/
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and
commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin,
musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates
activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps
restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®,
is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license
approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE
researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its
technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow
(lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic
tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and
orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s
shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development
activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact
regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any
such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are
beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are
risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical
and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues,
competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
CONTACT INFORMATION Millennium Park Capital LLC Christopher Wynne 312-724-7845 cwynne@mparkcm.com SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 investorrelations@sanuwave.com
